Understanding how NOTCH signaling affects prostate cancer transformation
NOTCH signaling controls transformation to androgen independent neuroendocrine prostate cancer
This study is looking into how prostate cancer can change into a tougher form after treatment, and it aims to find new ways to help patients by understanding the genetic changes involved.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Roswell Park Cancer Institute Corp NIH-funded |
| Lab location | 1 site (Buffalo, United States) |
| Project ID | NIH-10832072 on NIH RePORTER |
What this research studies
This research investigates the mechanisms behind the transformation of prostate adenocarcinoma to a more aggressive form known as neuroendocrine prostate cancer (NEPC). It focuses on how changes in NOTCH signaling and epigenetic reprogramming contribute to this transformation, particularly after patients undergo androgen deprivation therapy. By studying the genetic factors involved, the research aims to identify potential therapeutic targets that could restore sensitivity to existing treatments. Patients may benefit from insights that could lead to new treatment strategies for advanced prostate cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are men diagnosed with metastatic prostate adenocarcinoma who have experienced relapse and are at risk of developing neuroendocrine variants.
Not a fit: Patients with early-stage prostate cancer or those who have not undergone androgen deprivation therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that prevent or reverse the aggressive transformation of prostate cancer, improving patient outcomes.
How similar studies have performed: Other research has shown promising results in targeting epigenetic changes in cancer, suggesting that this approach may be effective in treating neuroendocrine prostate cancer as well.
Where this research is happening
Buffalo, United States
- Roswell Park Cancer Institute Corp — Buffalo, United States (Active)
Researchers
- Principal investigator: Goodrich, David W. — Roswell Park Cancer Institute Corp
- Study coordinator: Goodrich, David W.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.